Janssen Vaccines & Prevention B.v.

Beth Israel Deaconess Medical Center, Inc.

Janssen Pharmaceuticals, Inc.

Bavarian Nordic A/s

Frank Wegmann

Johannes Petrus Maria Langedijk

Jort Vellinga

Benoit Christophe Stephan Callendret

Anders Krarup

Danielle Van Manen

Jörn Stitz

Dan H Barouch

Jerald C Sadoff

Jerôme Hubertina Henricus Victor Custers

Markus Kalla

Lucy Rutten

David Adrianus Theodorus Maria Zuijdgeest

Viki Bockstal

Mathieu Claude Michel Le Gars

An Vandebosch

Rinke Bos

Mark Johannes Gerardus Bakkers

Roland Christian Zahn

Gijs Hardenberg

Benoit Christophe Callendret

Johannes Petrus Langedijk

Jorn Stitz

Benoit C S Callendret

Compositions and vaccine combinations containing synthetic HIV envelope proteins, and methods for inducing an immune response against human immunodeficiency virus (HIV) infection are described. Viral expression vectors encoding the synthetic HIV envelope proteins can be used in the vaccine combinations to induce immune responses against HIV and provide improved protective immunity against HIV.

Immunodeficiency virus type 1 (HIV-1) mutant envelope proteins

Poxvirus vectors encoding a synthetic HIV envelope antigen and other HIV antigens, as well as compositions containing such poxvirus vectors and uses of such poxvirus vectors as vaccines to provide improved immunity against HIV, are provided. Also provided are vaccine combinations containing the disclosed poxvirus vectors, adenovirus vectors encoding one or more HIV antigens, and one or more isolated HIV antigenic polypeptides, and methods of using the vaccine combinations to provide improved immunity against HIV.

Poxvirus vectors encoding HIV antigens, and methods of use thereof

Methods of inducing an immune response against human immunodeficiency virus (HIV) are described. In particular, methods of inducing an immune response against HIV by co-locally administering an immunogenically effective amount of an isolated HIV envelope (Env) polypeptide and an immunogenically effective amount of an adenovirus vector encoding an HIV antigen, e.g., Env antigen are described. The isolated HIV Env polypeptide and adenovirus vector can be administered in a single composition or in separate compositions, in which the composition or compositions do not contain an adjuvant.

Method of inducing an immune response against human immunodeficiency virus by co-localized administration of vaccine components

The invention relates to immunogenic compositions and vaccines containing a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; also referred to as SARS-CoV-2)) protein or a polynucleotide encoding a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) protein and uses thereof. The invention also provides methods of treating and/or preventing a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) infection by administering an immunogenic composition or vaccine to a subject (e.g., a human). The invention also provides methods of detecting and/or monitoring a protective anti-coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) antibody response (e.g., anti-coronavirus antibody response, e.g., anti-2019-nCoV antibody response, e.g., anti-Spike antibody response, e.g., anti-Spike neutralizing antibody response). The present invention relates to isolated nucleic and/or recombinant nucleic acid encoding a coronavirus S protein, in particular a SARS-CoV-2 S protein, and to the coronavirus S proteins, as well as to the use of the nucleic acids and/or proteins thereof in vaccines.

Compositions and methods for preventing and treating coronavirus infection&#x2014;SARS-CoV-2 vaccines

Recombinant adenoviruses encoding mosaic human immunodeficiency virus (HIV) Env, Gag, and Pol antigens

Synthetic HIV envelope proteins, vectors and compositions thereof, and methods for inducing protective immunity against human immunodeficiency virus (HIV) infection are described. Viral expression vectors encoding the synthetic HIV envelope proteins can be used in vaccines to provide improved protective immunity against HIV.

Synthetic human immunodeficiency virus (HIV) envelope antigen, vectors, and compositions thereof

Growing community of inventors

Leiden, Netherlands

Frank Wegmann